1 エグゼクティブ・サマリー
2 序文
2.1 概要
2.2 ステークホルダー
2.3 調査範囲
2.4 調査方法
2.4.1 データマイニング
2.4.2 データ分析
2.4.3 データの検証
2.4.4 リサーチアプローチ
2.5 リサーチソース
2.5.1 一次調査ソース
2.5.2 セカンダリーリサーチソース
2.5.3 前提条件
3 市場動向分析
3.1 はじめに
3.2 推進要因
3.3 抑制要因
3.4 機会
3.5 脅威
3.6 エンドユーザー分析
3.7 新興市場
3.8 Covid-19の影響
4 ポーターズファイブフォース分析
4.1 供給者の交渉力
4.2 買い手の交渉力
4.3 代替品の脅威
4.4 新規参入の脅威
4.5 競争上のライバル関係
5 ワクチンの世界市場、ワクチン種類別
5.1 はじめに
5.2 不活化ワクチン
5.3 活性化ワクチン
5.4 混合ワクチン
5.5 mRNA（メッセンジャーリボ核酸）ワクチン
5.6 DNA（デオキシリボ核酸）ワクチン
5.7 トキソイドワクチン
5.8 その他のワクチンタイプ
6 世界のワクチン市場、疾患種類別
6.1 はじめに
6.2 感染症
6.3 がんワクチン
6.4 自己免疫疾患
6.5 旅行関連ワクチン
6.6 その他の疾患タイプ
7 ワクチンの世界市場：投与経路別
7.1 導入
7.2 注射剤
7.3 経口
7.4 経鼻
7.5 経皮
8 ワクチンの世界市場、年齢層別
8.1 はじめに
8.2 小児
8.3 成人
8.4 老年
9 ワクチンの世界市場：エンドユーザー別
9.1 はじめに
9.2 病院
9.3 薬局
9.4 公衆衛生機関
9.5 研究機関
9.6 その他のエンドユーザー
10 ワクチンの世界市場、地域別
10.1 はじめに
10.2 北アメリカ
10.2.1 アメリカ
10.2.2 カナダ
10.2.3 メキシコ
10.3 ヨーロッパ
10.3.1 ドイツ
10.3.2 イギリス
10.3.3 イタリア
10.3.4 フランス
10.3.5 スペイン
10.3.6 その他のヨーロッパ
10.4 アジア太平洋
10.4.1 日本
10.4.2 中国
10.4.3 インド
10.4.4 オーストラリア
10.4.5 ニュージーランド
10.4.6 韓国
10.4.7 その他のアジア太平洋地域
10.5 南アメリカ
10.5.1 アルゼンチン
10.5.2 ブラジル
10.5.3 チリ
10.5.4 その他の南アメリカ地域
10.6 中東/アフリカ
10.6.1 サウジアラビア
10.6.2 アラブ首長国連邦
10.6.3 カタール
10.6.4 南アフリカ
10.6.5 その他の中東/アフリカ地域
11 主要開発
11.1 契約、パートナーシップ、提携、合弁事業
11.2 買収と合併
11.3 新製品上市
11.4 事業拡大
11.5 その他の主要戦略
12 企業プロフィール
12.1 Pfizer Inc.
12.2 Moderna Inc.
12.3 Johnson & Johnson
12.4 Sanofi Pasteur
12.5 GlaxoSmithKline （GSK）
12.6 AstraZeneca
12.7 Novartis AG
12.8 Merck & Co., Inc.
12.9 Bavarian Nordic
12.10 BioNTech SE
12.11 Serum Institute of India
12.12 CureVac N.V.
12.13 Abbott Laboratories
12.14 Clover Biopharmaceuticals
12.15 Inovio Pharmaceuticals
12.16 Indian Immunologicals Limited （IIL）
12.17 Bayer AG
12.18 Takeda Pharmaceutical Company Limited
12.19 Eli Lilly and Company
12.20 Sinovac Biotech
表一覧
表1 ワクチンの世界市場展望、地域別（2022-2030年） （$MN）
表2 ワクチンの世界市場展望、ワクチン種類別（2022-2030年） （$MN）
表3 ワクチンの世界市場展望：不活化ワクチン別（2022-2030年） （$MN）
表4 ワクチンの世界市場展望：生ワクチン種類別（2022-2030年） （$MN）
表5 ワクチンの世界市場展望：結合型ワクチン（2022-2030年） （$MN）
表6 ワクチンの世界市場展望、mRNA（メッセンジャーリボ核酸）ワクチン別 （2022-2030） （$MN）
表7 ワクチンの世界市場展望、DNA（デオキシリボ核酸）ワクチン別 （2022-2030） （$MN）
表8 ワクチンの世界市場展望、トキソイドワクチン別 （2022-2030） （$MN）
表9 ワクチンの世界市場展望：その他のワクチン種類別（2022-2030年） （$MN）
表10 ワクチンの世界市場展望：疾患種類別（2022-2030年） （$MN）
表11 ワクチンの世界市場展望：感染症別（2022〜2030年） （$MN）
表12 ワクチンの世界市場展望：癌ワクチン別（2022-2030年） （$MN）
表13 ワクチンの世界市場展望：自己免疫疾患別（2022-2030年） （$MN）
表14 ワクチンの世界市場展望：旅行関連ワクチン別 （2022-2030） （$MN）
表15 ワクチンの世界市場展望：その他の疾患種類別（2022〜2030年） （$MN）
表16 ワクチンの世界市場展望：投与経路別（2022〜2030年） （$MN）
表17 ワクチンの世界市場展望：注射剤別（2022〜2030年） （$MN）
表18 ワクチンの世界市場展望：経口剤別（2022〜2030年） （$MN）
表19 ワクチンの世界市場展望：経鼻剤別（2022-2030年） （$MN）
表20 ワクチンの世界市場展望：経皮（2022-2030年）別 （$MN）
表21 ワクチンの世界市場展望：年齢層別（2022-2030年） （$MN）
表22 ワクチンの世界市場展望：小児（2022-2030年）別 （$MN）
表23 ワクチンの世界市場展望：成人別（2022-2030年） （$MN）
表24 ワクチンの世界市場展望：老人（2022-2030年）別 （$MN）
表25 ワクチンの世界市場展望：エンドユーザー別（2022-2030年） （$MN）
表26 ワクチンの世界市場展望：病院別（2022-2030年） （$MN）
表27 ワクチンの世界市場展望：薬局別（2022-2030年） （$MN）
表28 ワクチンの世界市場展望：公衆衛生機関別（2022-2030年） （$MN）
表29 ワクチンの世界市場展望：研究機関別（2022-2030年） （$MN）
表30 ワクチンの世界市場展望：その他のエンドユーザー別（2022-2030年） （$MN）
注：北アメリカ、ヨーロッパ、APAC、南アメリカ、中東/アフリカ地域の表も上記と同様に表記しています。
According to the United Nations Health Agency, as of September 2021, only 3% of people had been vaccinated with at least one dose of the covid -19 vaccine, compared to 60.18% in high-income countries.
Market Dynamics:
Driver:
Rising incidence of infectious diseases
As new and re-emerging diseases spread, both governments and healthcare organizations prioritize vaccination to protect public health and mitigate outbreaks. This heightened need drives investments in vaccine research, development, and production. Additionally, increased disease prevalence raises public awareness and urgency, encouraging higher vaccination rates and expanding market opportunities. Consequently, pharmaceutical companies and research institutions are motivated to innovate and scale up vaccine solutions, further fueling market growth.
Restraint:
Adverse reactions and safety concerns
Adverse reactions and safety concerns in vaccines arise from individual responses, potential side effects, or rare complications. These issues can stem from vaccine components, manufacturing processes, or underlying health conditions. Such concerns may lead to public skepticism and decreased vaccine uptake. Negative reports and misinformation can further amplify fears, impacting overall vaccination rates. This reduced trust and lower demand can hamper market growth.
Opportunity:
Mounting government initiatives and funding
Governments allocate substantial resources to support vaccine R&D, facilitating the creation of innovative vaccines and faster response to emerging diseases. Public funding also helps reduce the cost of vaccine production and makes vaccines more accessible, particularly in underserved regions. Additionally, government-led immunization programs increase vaccination rates, boost public health, and drive market demand. These efforts collectively strengthen the vaccine supply chain and promote global health security, fostering overall market growth.
Threat:
High development and production costs
High development and production costs in vaccines arise from extensive research, clinical trials, and stringent regulatory requirements. Manufacturing involves complex processes, quality control, and specialized equipment, further increasing expenses. Consequently, high costs can slow market growth by restricting vaccine availability, impeding widespread immunization efforts, and limiting investments in new vaccine development and innovation.
Covid-19 Impact
The covid-19 pandemic significantly propelled the vaccines market by accelerating vaccine development and production, highlighting the critical role of rapid response in public health. The crisis led to unprecedented global collaboration and funding, resulting in the swift creation and distribution of covid-19 vaccines. This experience boosted interest and investment in vaccine research and infrastructure. However, it also exposed challenges such as vaccine distribution inequities and public hesitancy. Overall, the pandemic underscored the importance of vaccines and spurred advancements in the industry, influencing future market dynamics.
The pediatric segment is expected to be the largest during the forecast period
The pediatric segment is estimated to have a lucrative growth. Pediatric vaccines are immunizations specifically designed for children to protect against common and serious diseases. These vaccines are crucial for preventing illnesses such as measles, mumps, rubella, and whooping cough. Early vaccination helps establish immunity before children are exposed to these pathogens. Immunization schedules are carefully designed to ensure timely protection, contributing to overall public health and reducing disease outbreaks.
The research institutions segment is expected to have the highest CAGR during the forecast period
The research institutions segment is anticipated to witness the highest CAGR growth during the forecast period. In research institutions, vaccines are used to advance scientific understanding and develop new immunization technologies. These institutions conduct studies on vaccine efficacy, safety, and innovative delivery methods. They explore novel vaccine platforms, and investigate new targets for disease prevention. Research-driven vaccine development aims to address emerging and existing diseases, improving public health outcomes and advancing medical science.
Region with largest share:
The vaccines market in the Asia-Pacific region is experiencing rapid growth due to increasing healthcare investments, rising disease incidence, and expanding immunization programs. Governments are prioritizing vaccine accessibility and affordability, driven by high population density and emerging disease threats. Innovations in vaccine technology and robust public health initiatives further stimulate market expansion. The region remains a key area for vaccine development and distribution, reflecting its growing healthcare needs.
Region with highest CAGR:
The vaccines market in North America is robust, driven by advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development. The region benefits from strong government support, including funding and public health initiatives, as well as a high level of public awareness about vaccine benefits. The market is also fuelled by ongoing innovation and the rapid development of new vaccines. Overall, North America remains a leading player in the global vaccine market.
Key players in the market
Some of the key players profiled in the Vaccines Market include Pfizer Inc., Moderna Inc., Johnson & Johnson, Sanofi Pasteur, GlaxoSmithKline (GSK), AstraZeneca, Novartis AG, Merck & Co., Inc., Bavarian Nordic, BioNTech SE, Serum Institute of India, CureVac N.V., Abbott Laboratories, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Indian Immunologicals Limited (IIL), Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Sinovac Biotech.
Key Developments:
In January 2024, Indian Immunologicals Ltd (IIL), a wholly-owned subsidiary of National Dairy Development Board (NDDB), launched India’s ‘first’ indigenously developed Hepatitis A vaccine. Havisure is expected to play a key role to protect against the Hepatitis A virus, which primarily affects the liver. The vaccine is effective in preventing the disease and is recommended for children in routine immunisation.
In November 2022, Pfizer Inc. and BioNTech SE have advanced a promising vaccine candidate into clinical trials. Their new mRNA-based combination vaccine aims to tackle two significant respiratory illnesses: influenza and COVID-19. This vaccine, currently in Phase 1 trials, represents a notable step forward in public health innovation.
Vaccine Types Covered:
• Inactivated Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• mRNA (messenger Ribonucleic Acid) Vaccines
• DNA (Deoxyribonucleic Acid) Vaccines
• Toxoid Vaccines
• Other Vaccine Types
Disease Types Covered:
• Infectious Diseases
• Cancer Vaccines
• Autoimmune Diseases
• Travel-Related Vaccines
• Other Disease Types
Route of Administrations Covered:
• Injectable
• Oral
• Nasal
• Transdermal
Age Groups Covered:
• Pediatric
• Adult
• Geriatric
End Users Covered:
• Hospitals
• Pharmacies
• Public Health Organizations
• Research Institutions
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Vaccines Market, By Vaccine Type
5.1 Introduction
5.2 Inactivated Vaccines
5.3 Live Attenuated Vaccines
5.4 Conjugate Vaccines
5.5 mRNA (messenger Ribonucleic Acid) Vaccines
5.6 DNA (Deoxyribonucleic Acid) Vaccines
5.7 Toxoid Vaccines
5.8 Other Vaccine Types
6 Global Vaccines Market, By Disease Type
6.1 Introduction
6.2 Infectious Diseases
6.3 Cancer Vaccines
6.4 Autoimmune Diseases
6.5 Travel-Related Vaccines
6.6 Other Disease Types
7 Global Vaccines Market, By Route of Administration
7.1 Introduction
7.2 Injectable
7.3 Oral
7.4 Nasal
7.5 Transdermal
8 Global Vaccines Market, By Age Group
8.1 Introduction
8.2 Pediatric
8.3 Adult
8.4 Geriatric
9 Global Vaccines Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Pharmacies
9.4 Public Health Organizations
9.5 Research Institutions
9.6 Other End Users
10 Global Vaccines Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Pfizer Inc.
12.2 Moderna Inc.
12.3 Johnson & Johnson
12.4 Sanofi Pasteur
12.5 GlaxoSmithKline (GSK)
12.6 AstraZeneca
12.7 Novartis AG
12.8 Merck & Co., Inc.
12.9 Bavarian Nordic
12.10 BioNTech SE
12.11 Serum Institute of India
12.12 CureVac N.V.
12.13 Abbott Laboratories
12.14 Clover Biopharmaceuticals
12.15 Inovio Pharmaceuticals
12.16 Indian Immunologicals Limited (IIL)
12.17 Bayer AG
12.18 Takeda Pharmaceutical Company Limited
12.19 Eli Lilly and Company
12.20 Sinovac Biotech
List of Tables
Table 1 Global Vaccines Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Vaccines Market Outlook, By Vaccine Type (2022-2030) ($MN)
Table 3 Global Vaccines Market Outlook, By Inactivated Vaccines (2022-2030) ($MN)
Table 4 Global Vaccines Market Outlook, By Live Attenuated Vaccines (2022-2030) ($MN)
Table 5 Global Vaccines Market Outlook, By Conjugate Vaccines (2022-2030) ($MN)
Table 6 Global Vaccines Market Outlook, By mRNA (messenger Ribonucleic Acid) Vaccines (2022-2030) ($MN)
Table 7 Global Vaccines Market Outlook, By DNA (Deoxyribonucleic Acid) Vaccines (2022-2030) ($MN)
Table 8 Global Vaccines Market Outlook, By Toxoid Vaccines (2022-2030) ($MN)
Table 9 Global Vaccines Market Outlook, By Other Vaccine Types (2022-2030) ($MN)
Table 10 Global Vaccines Market Outlook, By Disease Type (2022-2030) ($MN)
Table 11 Global Vaccines Market Outlook, By Infectious Diseases (2022-2030) ($MN)
Table 12 Global Vaccines Market Outlook, By Cancer Vaccines (2022-2030) ($MN)
Table 13 Global Vaccines Market Outlook, By Autoimmune Diseases (2022-2030) ($MN)
Table 14 Global Vaccines Market Outlook, By Travel-Related Vaccines (2022-2030) ($MN)
Table 15 Global Vaccines Market Outlook, By Other Disease Types (2022-2030) ($MN)
Table 16 Global Vaccines Market Outlook, By Route of Administration (2022-2030) ($MN)
Table 17 Global Vaccines Market Outlook, By Injectable (2022-2030) ($MN)
Table 18 Global Vaccines Market Outlook, By Oral (2022-2030) ($MN)
Table 19 Global Vaccines Market Outlook, By Nasal (2022-2030) ($MN)
Table 20 Global Vaccines Market Outlook, By Transdermal (2022-2030) ($MN)
Table 21 Global Vaccines Market Outlook, By Age Group (2022-2030) ($MN)
Table 22 Global Vaccines Market Outlook, By Pediatric (2022-2030) ($MN)
Table 23 Global Vaccines Market Outlook, By Adult (2022-2030) ($MN)
Table 24 Global Vaccines Market Outlook, By Geriatric (2022-2030) ($MN)
Table 25 Global Vaccines Market Outlook, By End User (2022-2030) ($MN)
Table 26 Global Vaccines Market Outlook, By Hospitals (2022-2030) ($MN)
Table 27 Global Vaccines Market Outlook, By Pharmacies (2022-2030) ($MN)
Table 28 Global Vaccines Market Outlook, By Public Health Organizations (2022-2030) ($MN)
Table 29 Global Vaccines Market Outlook, By Research Institutions (2022-2030) ($MN)
Table 30 Global Vaccines Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
